Evidence map›Paper›PMID 42495531›Full record

ArticleiScience2026

KMT5A-mediated methylation of IRF3 promotes tumor progression through immune suppression.

Pengcheng Li, Chengxin Yu, Runshi Xie, Changsheng Huang, Qi Wu, Anyi Liu, Xiaowei She, Mao Li, Zejun Rao, Lang Liu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Pengcheng LiGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, China.
Chengxin YuGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, China.
Runshi XieGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, China.
Changsheng HuangGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, China.
Qi WuGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, China.
Anyi LiuGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, China.
Xiaowei SheGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, China.
Mao LiGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, China.
Zejun RaoGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, China.
Lang LiuGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, China.
Guihua WangGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, China.
Junbo HuGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, China.
Li SunDepartment of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lysine methylation is a critical post-translational modification (PTM) involved in diverse physiological and pathological processes. Interferon regulatory factor 3 (IRF3) plays a pivotal role in antitumor immunity; however, the regulatory mechanisms and functional impact of IRF3 methylation within the tumor microenvironment remain incompletely understood. This study demonstrates that monomethylation of IRF3 at lysine 193(K193) suppresses its phosphorylation-dependent activation. Mass spectrometry-based protein interactome analysis identified lysine methyltransferase 5A (KMT5A) as the key enzyme responsible for IRF3 K193 monomethylation. In colorectal cancer (CRC), aberrantly high expression of KMT5A impaired

Indexed as

Biological sciencescancerEpigenetics

Identifiers

PMID42495531
PMCPMC13392861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.